The high-profile industry move comes as Pfizer and other vaccine makers scramble to assess how their shots will stand up to a new variant of the coronavirus that causes Covid-19.
The high-profile industry move comes as Pfizer and other vaccine makers scramble to assess how their shots will stand up to a new variant of the coronavirus that causes Covid-19.
Share this Article
Recommended